Biohaven Pauses Epilepsy Trials

Biohaven has paused new enrollment in its epilepsy trials due to a partial clinical hold imposed by the FDA. The hold affects the company's ongoing trials for an epilepsy treatment.

The FDA's decision to impose a partial clinical hold has significant implications for Biohaven's research and development efforts. The company will need to address the concerns raised by the FDA before it can resume new enrollment in its epilepsy trials.

## What happens next The pause in new enrollment is a setback for Biohaven, but it does not necessarily mean that the trials will be discontinued. The company will likely work to resolve the issues that led to the partial clinical hold and seek to resume the trials as soon as possible.

The FDA's partial clinical hold is a regulatory action that allows the agency to pause or slow down a clinical trial due to concerns about the safety or efficacy of the treatment being tested. In this case, the hold only affects new enrollment, and patients who are already participating in the trials may be allowed to continue.

## Why it matters The development of new treatments for epilepsy is crucial for improving the lives of patients with the condition. Epilepsy is a neurological disorder that affects millions of people worldwide, and there is a significant need for effective and safe treatments. Biohaven's epilepsy trials were aimed at addressing this need, and the pause in new enrollment may impact the timeline for bringing a new treatment to market.

The FDA's regulatory actions are in place to ensure that new treatments are safe and effective for patients. While the partial clinical hold may be a setback for Biohaven, it is an important step in ensuring that any new treatment meets the required standards for safety and efficacy.